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Randomized Controlled Trial to Determine
the Impact of Probiotic Administration on
Colonization With Multidrug-Resistant
Organisms in Critically Ill Patients
Jennie H. Kwon, DO;1 Kerry M. Bommarito, PhD, MPH;1
Kimberly A. Reske, MPH;1 Sondra M. Seiler, BA;1
Tiffany Hink, BS;1 Hilary M. Babcock, MD, MPH;1
Marin H. Kollef, MD;2 Victoria J. Fraser, MD;1
Carey-Ann D. Burnham, PhD;3 Erik R. Dubberke, MD,
MSPH1 for the Centers for Disease Control and Prevention
(CDC) Prevention Epicenters
This was a randomized controlled pilot study of Lactobacillus
rhamnosus GG versus standard of care to prevent gastrointestinal
multidrug-resistant organism colonization in intensive care unit
patients. Among 70 subjects, there were no signiﬁcant differences in
acquisition or loss of any multidrug-resistant organisms (P> .05) and
no probiotic-associated adverse events.
Infect. Control Hosp. Epidemiol. 2015;36(12):1451–1454
Infections with multidrug-resistant organisms (MDROs) are a
serious threat to critically ill patients, leading to increased
morbidity and mortality.1,2 Gastrointestinal colonization with
MDROs increases patients’ risk of infection, and colonized
patients are the major reservoir for MDRO transmission to
other hospitalized patients.3 One potential strategy to prevent
MDRO colonization is to use probiotics to promote healthy
intestinal ﬂora, but data on probiotics in intensive care unit
(ICU) patients are limited. We conducted a prospective,
randomized controlled pilot study to determine whether
Lactobacillus rhamnosus GG could safely prevent intestinal
colonization with MDROs in a critically ill population.
methods
This study was conducted at Barnes-Jewish Hospital in
St. Louis, Missouri, a 1,250-bed university-afﬁliated hospital,
from February 2012 through October 2013 and was approved
by the Washington University Human Research Protection
Ofﬁce. The primary outcome was the acquisition of gastro-
intestinal MRDO colonization. The secondary end points were
safety and loss of MDRO colonization.
Inpatients aged at least 18 years admitted to the medical
or coronary ICUs with anticipated length of stay greater
than 48 hours were eligible. Exclusion criteria included
pregnancy, immunosuppression, human immunodeﬁciency
virus infection with CD4 less than 200 cells/mcL, absolute
neutrophil count less than 500 K/mm3, transplant recipients,
ongoing chemotherapy, prosthetic valve or valvuloplasty,
vascular graft, left ventricular assist device, balloon pump,
cardiac arrest, cardiac trauma, pancreatitis, endocarditis,
history of rheumatic fever, congenital cardiac abnormality,
tracheostomy, gastrointestinal bleeding or injury, esophageal
varices, oropharyngeal mucosal injury, diarrhea, and unwillingness
or inability to consent.
Subjects were randomly assigned to the probiotic or
standard of care (SOC) group in a 1:1 ratio using permutation
blocks (4 per block) by Acute Physiology and Chronic Health
Evaluation II scores. Study assignment was not masked.
Subjects randomized to the probiotic group received 1 capsule
containing 1 × 1010 cells of L. rhamnosus GG (Culturelle;
i-Health) twice a day. If subjects were unable to swallow owing
to intubation or presence of a nasogastric tube, the probiotic
was administered in a saline slurry via syringe through the tube
after removal of the gelatin capsule. Subjects in the probiotic
group received probiotic for 14 days or until study exit (death
or hospital discharge), whichever came ﬁrst.
Stool samples or rectal swab samples were obtained at study
enrollment (prior to the ﬁrst dose of probiotic), study day 3,
and every 3 days until study exit. Study exit was deﬁned as
death or day 14 after enrollment, whichever came ﬁrst.
Patients were included in outcomes analyses if they had at least
3 samples. Acquisition of MDRO was deﬁned as negative
culture results on enrollment and positive culture results on
day 3 and/or at study exit. Loss of MDRO colonization was
deﬁned as positive culture results on enrollment and negative
culture results on day 3 and study exit.
Selective media were used to isolate MDROs as follows: for
carbapenem-resistant Enterobacteriaceae, HardyCHROM
CRE Agar (Hardy Diagnostics); for vancomycin-resistant
Enterococcus (VRE), ChromID VRE Agar (bioMérieux); for
extended-spectrum beta-lactamase (ESBL), HardyCHROM
ESBL Agar (Hardy Diagnostics); and for Pseudomonas,
HardyCHROM ChromID Pseudomonas Agar (bioMérieux).
Cycloserine-cefoxitin mannitol broth with taurocholate
lysozyme cysteine (Anaerobe Systems) was used for Clostridium
difﬁcile culture as previously published.4 Organisms recovered
from selective media were identiﬁed using the Vitek MS
matrix-assisted laser desorption ionization–time of ﬂight mass
spectrometry system, IVD version 2.0 (bioMérieux).
Data collected included demographic characteristics,
medical history, Acute Physiology and Chronic Health
Evaluation II scores, length of stay, type of ICU, inpatient
medication exposures, ventilation status, hospital mortality,
and diagnosis of infections due to L. rhamnosus GG. The
χ2 test, univariate logistic regression, and Mann-Whitney test
were performed as appropriate. P≤ .05 was considered
signiﬁcant. SPSS, version 21 (IBM), was used.
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results
One hundred three patients were enrolled and randomized
to probiotics or SOC. Seventy patients had at least 3 specimens
available for analyses: 30 (43%) in the probiotic group
and 40 (57%) in the SOC group (Figure 1). There were no
signiﬁcant differences between groups in demographic
characteristics, pre-enrollment length of stay, or severity of
illness (Table 1). There was a trend towards older age in the
probiotic group (median age, 65 vs 59 y; P= .06). Patients in
the probiotic group were more likely to have received aztreo-
nam before enrollment (17% vs 0%; P= .01) (Table 1).
Colonization status throughout enrollment is summarized in
Table 2. There was no signiﬁcant difference in colonization with
any MDROs on enrollment (43% of probiotic group vs 33% of
SOC group; P= .35). Only 1 subject was colonized with an ESBL
and 1 with Pseudomonas aeruginosa at enrollment. More patients
were colonized with VRE and C. difﬁcile, and rates were similar
between groups (P= .34 and P= .80, respectively).
There was no signiﬁcant difference in overall acquisition of any
MDROs between the 2 groups (10% of probiotic group vs 15%
of SOC group; P= .72). Two patients (7%) in the probiotic group
acquired ESBL colonization (P= .19). Seventeen percent of the
probiotic group vs 9% in the SOC group acquired VRE (P= .42).
Seven percent of the probiotic group and 8% of the SOC group
acquired P. aeruginosa (P> .99). No patients in the probiotic
group and 6% in the SOC group acquired C. difﬁcile (P= .50).
The single patient colonized with an ESBL-producing
Enterobacteriaceae on enrollment (SOC group) remained
colonized throughout hospitalization. No patients in any
group lost colonization with VRE or P. aeruginosa. One SOC
patient lost C. difﬁcile colonization (P> .99).
All 103 patients were included in the safety assessment.
There were no signiﬁcant differences between probiotic and
SOC patients in the number of patients who died (22% pro-
biotic group vs 21% SOC; P= .88). There were no infections
due to probiotic or clinical cultures positive for L. rhamnosus
GG in either group. No adverse events associated with the
probiotic occurred.
discussion
No differences in acquisition or loss of MDRO colonization
between the probiotic and SOC group were identiﬁed in this
study. These results may indicate that either our sample size was
not large enough to detect a difference between groups, our
study duration was too short, or that L. rhamnosus GG at the
dose used did not affect MDRO colonization. There were no
infections related to probiotics, suggesting that probiotics may be
safe in a select cohort of critically ill patients, with care to mini-
mize probiotic contamination when administered by tube.
Previous studies evaluating probiotics have had conﬂicting
results.5–8 A meta-analysis found that probiotics in critically ill
table 1. Pre-enrollment Patient Characteristics
Variable Probiotic (n= 30) Standard of care (n= 40) P value
Age, median (range), y 65 (29–82) 59 (32–82) .06
Female sex 18 (60) 20 (50) .41
Nonwhite race 11 (37) 16 (40) .78
Pre-enrollment hospital LOS, median (range), d 6.0 (1–17) 4.5 (1–23) .31
Pre-enrollment ICU LOS, median (range), d 4.5 (1–16) 3.5 (1–22) .18
Patient location
Cardiac ICU 13 (43) 14 (35) Reference
Medical ICU 17 (57) 26 (65) .48
Pre-enrollment mechanical ventilation 20 (67) 20 (50) .16
APACHE II
1–17 12 (40) 17 (43) Reference
18–24 12 (40) 15 (38) .82
≥25 6 (20) 8 (20) .93
Pre-enrollment medication exposures ≥12 hours
Aztreonam 5 (17) 0 (0) .01
Carbapenems 4 (13) 6 (15) > .99
Cephalosporins 12 (40) 20 (50) .41
Metronidazole PO/IV 5 (17) 2 (5) .13
Penicillins 2 (7) 3 (8) > .99
Vancomycin IV 13 (43) 18 (45) .89
Any antibiotic 22 (73) 25 (63) .34
PPI/H2 blocker 20 (67) 25 (63) .72
NOTE. Data are no. (%) of subjects unless otherwise indicated. APACHE II, Acute Physiology and Chronic Health Evaluation
II; H2 blocker, H2 receptor antagonists; ICU, intensive care unit; IV, intravenous; LOS, length of stay; PO, by mouth;
PPI, proton pump inhibitor.
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adults did not signiﬁcantly reduce mortality but did reduce
ICU-acquired pneumonia and ICU length of stay.9 Another
meta-analysis indicated probiotics were associated with reduc-
tions in infectious complications but had no effect on mortality
or length of stay.10 These differences may be due to varying
sample size, rates of MDRO carriage, types and doses of
probiotic used, or the underlying complexity of the microbiome.
This study has limitations, including small sample size,
duration of follow-up, and inclusion of a single type and dose
of probiotic. We did not survey for gastric or upper airway
colonization, which may be an important site for MDRO
colonization. Finally, our extensive exclusion criteria may limit
the generalizability of this study.
There are unresolved controversies regarding probiotics,
including the type of patients who may beneﬁt most from pro-
biotics, the ideal probiotic organism(s), and the dose. The effect
of prolonged probiotic administration on the gut microbiome is
an area for further investigation. Larger studies are needed to
evaluate the effectiveness of probiotics in preventing intestinal
colonization due to MDROs in critically ill patients.
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